A new study shows that a personalized messenger RNA (mRNA) cancer vaccine plus the checkpoint inhibitor Keytruda (pembrolizumab) reduced the risk of recurrence or death in people with high-risk advanced melanoma.
The U.S. Food and Drug Administration has amended the emergency use authorizations of the. Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.
A large clinical trial of Eli Lilly's experimental Alzheimer's medication, donanemab found the drug slowed declines in patients' ability to think clearly and perform daily tasks by more than a third.
Findings in a recent study suggest that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus.
A new study shows that a protein called glial fibrillary acidic protein is a possible biomarker for very early stages of Alzheimer's.
Investigators have found that a subset of mutations within the overall tumor mutation burden are less likely to be edited out as cancer evolves.
The Centers for Disease Control and Prevention updated its schedule of recommended immunizations to include COVID-19 shots and boosters for children, adolescents and adults.
The first clinical trial for Down syndrome regression disorder is being funded by a five-year $5.3 million grant.
The Office for Civil Rights issued a bulletin to highlight the obligations of the Health Insurance Portability and Accountability Act of 1996 on covered entities and business associates when using online tracking technologies.
The U.S. Department of Health and Human Services has awarded nearly $245 million in Bipartisan Safer Communities Act funding to support the integration of mental health training into the training of primary care clinicians.
The U.S. Department of Health and Human Services has awarded $13 million to bolster nursing education and training to grow the nursing workforce and improve access to nursing education.
Infusion of CSL112, an investigational human plasma-derived apolipoprotein A-1 formulated with phosphatidylcholine, rapidly and strongly elevates impaired cholesterol efflux capacity following acute myocardial infarction.
